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Abstract: The chemokine and adhesion molecule fractalkine and its receptor CX3CR1 
have emerged as interesting regulators in inflammation and related atherosclerosis. The 
pro-inflammatory status may be counteracted by appropriate treatment, such as in rehabilitation. 
We compared serum fractalkine concentrations of 46 patients with coronary heart disease 
(CHD) and 47 insulin-dependent diabetic patients (IDDM) following rehabilitation with those 
of 50 control subjects. Following rehabilitation serum fractalkine levels (477 ± 225 pg/mL) in 
CHD patients were similar to those in control subjects (572 ± 205 pg/mL; P = 0.303), whereas 
fractalkine levels were lower in IDDM patients (430 ± 256 pg/mL; P = 0.042). No significant 
difference between CHD and IDDM patients was present (P = 0.319). Postprandial hyperlipemia 
may influence inflammation; thus, we investigated fractalkine levels four and eight hours after 
inducing postprandial hyperlipemia. However, we did not find any significant alterations in 
CHD and diabetic patients, whereas the fractalkine levels in controls were reduced. In vitro, 
lipofundin used as a hyperlipemic stimulus was added to vessel wall cells and reduced fractalkine 
levels. Low fractalkine levels in patients attending rehabilitation indicate a beneficial effect 
of the rehabilitation procedure on innate inflammatory pathways, such as the chemokine and 
adhesion molecule fractalkine.
Keywords: inflammation, cytokines, atherosclerosis, fractalkine, coronary heart disease, 
diabetes, rehabilitation
Introduction
Atherosclerosis is a multifactorial disease of the blood vessel wall that is strongly 
influenced by inflammatory pathways,1,2 such as adhesion of leukocytes to the 
endothelium, and other inflammatory or innate mechanisms.3,4 During atherogenesis, 
monocytes accumulate in the neointima and subsequently transform into tissue 
macrophages/foam cells. In addition, other leukocytes, such as mast cells5 or T-cells,6 
are also found in atherosclerotic lesions. The invasion of the vessel wall starts when 
blood cells adhere to the endothelium. However, the mechanisms underlying the initial 
activation have still not been completely defined. The leukocyte-endothelial interaction 
involves rolling, firm adhesion, and migration into the neointima, which is mediated 
by selectins and other adhesion molecules7 as well as by chemokines.8 Chemokines 
attract and direct cells along a chemotactic gradient. Furthermore, they may activate 
other atherosclerosis-relevant functions of vessel wall cells or leukocytes, for example, 
by activating adhesion molecules on the endothelium.8,9Vascular Health and Risk Management 2009:5 850
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The recently discovered chemokine fractalkine10 and its 
receptor CX3CR1 have emerged as interesting intermediaries 
in atherosclerosis. Fractalkine is a multidomain pro-
tein expressed on the surface of a variety of cells, including 
activated endothelial and smooth muscle cells.11–15 Fractalkine 
exhibits features which have not been described for other 
members of the chemokine family, including its exceptionally 
large size of 95 kDa and the presence of a transmembrane 
anchor. Furthermore, a soluble form can be released from 
its membrane-associated form by extracellular cleavage.16 
CX3CR1 is a seven-transmembrane-spanning fractalkine 
receptor, mediating its signal by G-proteins, as most 
cytokines do. This receptor mediates the firm adhesion to 
fractalkine even in the absence of G-protein activation17 
and thus plays a role as an adhesion molecule in addition to 
functioning as a chemokine. In this way, membrane-bound 
fractalkine contributes to the adhesion of CX3CR1-expressing 
leukocytes. On the other hand, soluble fractalkine, after 
enzymatic cleavage and release, has potent chemotactic 
activity for monocytes and lymphocytes but, like CC 
chemokines, not for granulocytes.18
Cytokines, including chemokines, and other innate 
compounds are strongly involved in the inflammatory 
pathways contributing to atherosclerosis.4,7,8 Thus, evidence 
has been provided that fractalkine plays a role in various 
cardiovascular diseases. For example, increased fractalkine 
levels have been reported in patients after cardiac allograft 
rejection. In a murine model, allograft survival was 
prolonged from 7 ± 1 days to 49 ± 30 days (P  0.0008) by 
administering fractalkine antibodies.19 These studies identi-
fied a critical role for fractalkine in the pathogenesis of acute 
rejection and suggest that fractalkine inhibition might be a 
potential therapeutic target. Fractalkine levels have only been 
rarely determined in patients; however, it has been shown 
that Alzheimer patients express enhanced fractalkine levels, 
correlating with the Mini-Mental State Examination (MMSE) 
score.20 Another study also reported that fractalkine levels 
are enhanced in Wegener’s granulomatosis.21 In patients 
with coronary artery disease fractalkine plasma levels were 
enhanced and then reduced after statin therapy.22 When 
CX3CR1 genotypes were analyzed in patients with acute 
coronary syndromes and healthy controls, CX3CR1-I249 
heterozygosity was associated with a markedly reduced 
risk of acute coronary events, independent of established 
coronary risk factors such as smoking or diabetes.23,24
Both the risk and the rate of development of athero-
sclerosis are increased in diabetic patients, but the under-
lying mechanisms are still not completely understood. 
Epidemiologic and pathophysiologic evidence suggests that 
lipoproteins, platelets, or soluble clotting factors represent 
contributing factors. Furthermore, both balance of the 
prostaglandin-metabolites prostacycline and thromboxane 
and blood pressure regulation are disturbed. On the other 
hand, the metabolism and proliferation of arterial smooth 
muscle cells are modified.25 Many of these alterations 
accompany hyperinsulinemia and may account for the 
recent evidence that hyperinsulinemia is a risk factor for 
atherosclerosis. Cytokines and chemokines may contribute 
to regulate atherosclerosis-related pathways in diabetes or 
its associated diseases.26,27 However, little is known about 
the expression of fractalkine and its receptor in diabetes, 
although the mRNA of fractalkine and its receptor were 
upregulated in diabetic rats in the early stages of diabetic 
nephropathy.28
To the best of our knowledge, fractalkine levels have 
not yet been analyzed in patients with insulin-dependent 
diabetes following rehabilitation. An optimized medical 
treatment consisting of medication such as angiotensin-
converting enzyme (ACE) inhibitors, angiotensin-receptor 
blockers (ARBs), and statins plays an important role 
during rehabilitation. Some of the aforementioned drugs 
may also exert anti-inflammatory properties, which could 
contribute to their beneficial effects. Indeed, fractalkine 
levels were reduced in patients with coronary artery disease 
after a six-week statin treatment.22 Thus, rehabilitation may 
normalize levels of fractalkine.
In diabetic patients postprandial hyperlipemia may 
represent a potential risk factor for atherosclerosis.29 Post-
prandial hyperlipemia can induce an inflammatory state 
by activating granulocytes,30 leukocytes,31 or endothelial 
cells.32 Triglyceride-rich lipids (TRL) may even penetrate 
the arterial wall and activate vascular smooth muscle cell 
genes differently, depending on the composition (ie, butter, 
vegetable oil/fish oil, or olive oil) of the lipid.33 Furthermore, 
chylomicron remnants containing TRLs have been shown to 
potently activate smooth muscle cell MCP-1 production.34 
Postprandial hyperlipemia may promote inflammation in 
patients and oppose therapy. However, it is not clear whether 
therapy during rehabilitation may prevent postprandial 
hyperlipemia from inducing inflammation.
Thus, in the present study we investigated the expression 
of serum fractalkine in patients with coronary heart disease 
(CHD) and patients with insulin-dependent diabetes following 
optimized medical treatment after a period of rehabilitation. 
Subsequently, we analyzed the effect of postprandial 
hyperlipemia. We found that fractalkine levels in CHD and Vascular Health and Risk Management 2009:5 851
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diabetic patients after rehabilitation were comparable to 
those in control subjects and that the postprandial fractalkine 
levels were not significantly increased. However, postprandial 
fractalkine levels in control subjects were reduced, a finding 
paralleled by in vitro cell culture data. These data indicate that 
the anti-inflammatory effects of the rehabilitation medication 
played an important role in the study patients.
Material and methods
study population
We determined the serum concentrations of fractalkine 
in 46 nondiabetic patients with angiographically proven 
CHD, 47 insulin-dependent diabetic patients (IDDM), 
and 50 healthy controls. The patients were recruited in the 
“Curschmann Klinik für Rehabilitation” (Timmendorfer 
Strand/Germany). The control subjects were volunteers 
(mostly working at the Curschmann Clinic) with no prove 
of CHD or diabetes mellitus. The study was approved by 
the ethics committee of the University of Lübeck, Schleswig 
Holstein, Germany. All patients gave written informed 
consent.
Blood sampling and clinical laboratory 
parameters
Blood samples were taken from all subjects under 
standardized conditions after an overnight period of fasting 
(time-zz [compared below]). The next blood samples were 
taken four and eight hours later. All blood samples were 
immediately centrifuged at 4,000 rpm for 10 minutes, 
supernatants were extracted and divided into aliquots. 
All aliquots were stored at -80 °C until analysis. The 
fractalkine levels in the samples were measured by using 
a sandwich ELISA (enzyme-linked immunosorbent assay; 
DuoSet, R&D Systems, Wiesbaden, Germany) according to 
the manufacturer’s recommendations. Besides fractalkine, 
atherosclerosis-relevant serum markers of inflammation 
(C-reactive  protein  [CRP])  and  lipid  metabolism 
(low-density lipoprotein cholesterol [LDL-C]; high-density 
lipoprotein cholesterol [HDL-C]; total cholesterol [TC]; 
and triglycerides [TG]) were measured. The lipid markers 
were routinely determined by standard clinical laboratory 
analysis.
induction of postprandial hyperlipemia
Postprandial hyperlipemia was induced by eating a high 
calorie fatty meal. Briefly, the meal contained a total of 
1,265 kcal/m2 body surface area. It was composed of 
105 g fat (consisting of approximately 52 g saturated 
fat, 53 g unsaturated fat, and 300 mg cholesterol), 48 g 
carbohydrates, and 32 g protein. Probands were instructed 
to eat the meal within 15 minutes and not to eat any other 
food until the subsequent blood samples were taken. Before 
the meal (time-point 0) the diabetic patients received a dose 
of insulin subcutaneously, which was individually adapted 
to the meal described above. Glucose levels were measured 
every two hours until the end of the study period in order to 
prevent severe hypo- or hyperglycemia. All glucose levels 
were in an acceptable range; thus, no glucose or further insulin 
administration was required until the end of the eight-hour 
study period.
isolation and culture of human vascular 
vessel wall cells
Human vascular smooth muscle cells were isolated from 
unused portions of saphenous veins obtained following 
bypass surgery, as described previously.35,36 Use of the 
specimens that would otherwise have been discarded 
was approved by the local ethics committee. Dulbecco’s 
modified Eagle’s medium (DMEM; 1 g/L D-glucose) 
containing 10% fetal calf serum (FCS), 1% antibiotics, 
and 1% l-glutamine (DMEM medium) was used for cell 
culture. Upon confluency the cells were subcultured after 
treatment with trypsin/EDTA (0.05% 0.02%, 10 minutes, 
37 °C, Biochrom, Berlin, Germany). We used smooth 
muscle cells in passages 4 to 7. Stimulation experiments 
were performed in 24-well culture plates as specified in 
Figure 3. Lipofundin LCT-10 solution was obtained from 
Braun (Melsungen, Germany).
statistical analysis
Statistical analysis was performed with the Statistical 
Package for the Social Sciences (SPSS Inc, Chicago, IL, 
USA). Continuous variables were compared by ANOVA. 
Chi-squared test was used for categorical variables. 
Correlation analysis was conducted according to the Pearson 
method.
Results
Baseline characteristics
The demographic data for the study populations are presented 
in Table 1. Compared with CHD patients and control 
subjects, the IDDM patients were older. The BMI was not 
significantly different, and the distribution of sexes was 
similar among the three groups. More smokers were found Vascular Health and Risk Management 2009:5 852
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among the healthy control subjects than in the two patient 
groups. On the other hand, more subjects with hypertension 
or a family history of CHD were present in the patient groups. 
As anticipated, medical treatment with statins, β-blockers, 
ACE inhibitors, ARBs, and diuretics was more prevalent 
in the patient groups. Except for diuretics, medication was 
similar in the tested patient groups. Healthy controls did 
not suffer from any obvious atherosclerotic, metabolic, 
or inflammatory disease.
The fractalkine levels in diabetic patients 
are lower than in healthy control subjects
Fractalkine levels have not been measured yet in diabetic 
patients following rehabilitation. Thus, we analyzed the 
expression of fractalkine in the IDDM and CHD patients 
who received optimal medical treatment and underwent 
rehabilitation for four weeks. The fractalkine levels of the 
patients were compared to those of the control subjects. 
A comparison of the fractalkine levels in CHD and IDDM 
patients after rehabilitation and healthy controls (time-
point 0) is shown in Figure 1. At this time-point fractalkine 
levels were slightly but not statistically significantly lower 
in CHD patients (477 ± 225 pg/ml) than in control subjects 
(527 ± 205 pg/ml; P = 0.303). In contrast, they were lower 
in IDDM patients than in the controls (430 ± 256 pg/ml; 
P = 0.042), whereas they were not significantly different 
from fractalkine levels in CHD patients (IDDM vs 
CHD; P = 0.319). Thus, fractalkine levels in both patient 
groups were below or equal to control levels.
Postprandial hyperlipemia does  
not reduce fractalkine levels  
in iDDM and cHD patients
Hyperlipemia can activate inflammatory pathways. However, 
it was unclear whether postprandial hyperlipemia affects 
inflammatory parameters in rehabilitation patients as 
compared to control subjects. Thus, after the first blood 
sample was taken (time-point 0), a defined postprandial 
hyperlipemia was induced in the three investigated groups. 
Four and eight hours after the first blood sampling and eating 
the defined meal the next samples were taken (time-point 4; 
time-point 8). At time-point 4 the fractalkine levels were 
higher in diabetic patients (548 ± 300 pg/mL) than in CHD 
patients (437 ± 228 pg/mL; P = 0.033); however, they were 
not different from the control levels (474 ± 203 pg/mL; 
Figure 2). At time-point 8 the fractalkine levels were 
432 ± 212 pg/mL in the CHD group, 454 ± 262 pg/mL in 
the IDDM group, and 393 ± 166 pg/ml in the control group. 
These values were not significantly different from each 
other. Comparing each group at the different time-points 
by ANOVA revealed that only the differences in the values 
for healthy control subjects were statistically significant 
(P = 0.004). Post hoc analysis showed that the fractalkine 
Table 1 characteristics of the investigated study populationsa
Parametersb Unit Control IDDM CHD P valueb
Age years 52.7 ± 11 64.0 ± 9 55.5 ± 9 0.001
BMi 26.6 ± 5 28.2 ± 5 26.8 ± 4 0.136
Male % 82 78 84 0.735
Active smokers % 34 10 2 0.001
Hypertension % 20 90 98 0.001
cHD-FH % 6 18 42 0.001
statins % 4 96 96 0.001
β-Blockers % 10 68 98 0.001
Ace inhibitors % 8 62 56 0.001
ARB % 2 14 16 0.001
Diuretics % 10 42 20 0.001
Notes: aPatients with insulin-dependent diabetes (iDDM; n = 47) or coronary heart 
disease (cHD; n = 46) were compared to healthy controls (n = 50).   Values are 
presented as mean ± standard deviation; bThe p-value for comparison between all 
three groups was calculated by AnOVA.   The values of the categorical variables are 
compared by chi-squared test.
Abbreviations: Ace, angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker;    AnOVA,  analysis of variance; BMi, body mass index; cHD-FH,  family history 
of coronary heart disease.
Figure 1 Fraktalkine levels in patients following rehabilitaiton are not higher than 
fractalkine levels in healthy control subjects. Blood samples of diabetic patients (iDDM; 
n = 47) and coronary heart disease patients (cHD; n = 46) following rehabilitation 
and blood samples of apparently healthy volunteers (con; n = 50) were measured by 
fractalkine ELISA. Mean and standard error of the mean are presented. Significances 
are given above the columns.
Abbreviations: cHD, coronary heart disease; con, control; eLisA, enzyme-linked 
immunosorbent assay; iDDM, insulin-dependent diabetic patients.
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levels at time-point 8 were different from those at time-point 4 
(P = 0.046) and time-point 0 (P = 0.001), whereas at time-
points 0 and 4 they were not significantly different. In contrast 
to control subjects, ANOVA analysis of IDDM and CHD 
patients did not reveal significant differences between the 
three time-points (P = 0.080 and P = 0.574, for diabetes and 
CHD, respectively). Post hoc analysis showed the same result 
at the 0.01 level. However, the IDDM time-points 0 and 4 
were different at the 0.05 level (P = 0.033). Taken together, 
the data indicate that the fractalkine levels were only reduced 
in control subjects, whereas in CHD the levels remained 
low and in IDDM patients the levels fluctuated, although 
the differences were not significant according to ANOVA. 
In order to investigate the influence of hyperlipemia in vitro 
we incubated vascular smooth muscle cells, which represent 
a potential source of fractalkine in atherogenesis, with several 
lipofundin concentrations. We observed a dose-dependent 
reduction in fractalkine production (Figure 3).
The fractalkine levels in the tested subjects 
do not correlate with cRP and lipids
The analysis of inflammatory and lipid markers at time-point 
0 is presented in Table 2. The CRP levels were higher 
in the diabetic patients (10 ± 16 mg/L) than in CHD 
patients (6 ± 7 mg/L; P = 0.025) and controls (2 ± 3 mg/L; 
P  0.001). All lipid parameters were highest in the healthy 
control subjects. The differences between controls and 
IDDM patients were less pronounced than the differences 
between controls and CHD patients. These data indicate that 
the lipid-lowering aspect of the IDDM and CHD medication 
worked properly. The correlation analysis revealed that there 
was no significant correlation between fractalkine serum 
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Figure 2 induction of postprandial hyperlipemia reduces fractalkine levels in healthy control subjects, but not in patients following rehabilitation. Blood samples of iDDM and 
cHD patients following rehabilitation and blood samples of healthy subjects (con) were collected at time-point 0. immediately thereafter a postprandial hyperlipemia was 
induced by a defined meal of 1,285 kcal/m2 body suface (105 g fat + 300 mg cholesterol + 48 g carbohydrates + 32 g protein.   At two time-points later (four and eight hours, 
respectively) blood samples were taken and measured by fractalkine eLisA. Data are presented as a box blot (sigmaPlot). The whiskers and box lines indicate the 10th, 25th, 
median, 75th, and 90th percentiles. The broken line indicates the mean. Extra symbols indicate outliers.   Analysis by one-way ANOVA showed a significant difference between 
the fractalkine levels at the time-points of the control subjects (p = 0.004), whereas levels for the diabetic (p = 0.080) and the cAD (p = 0.574) patients were not significantly 
different at the given time-points. Post-hoc analysis at the 0.01 level showed the same result; however, diabetic patients at the time-point 0 and 4 were different at the 0.05 level 
(p = 0.033).
Abbreviations:  AnOVA, analysis of variance; cAD, coronary artery disease; cHD, coronary heart disease; con, control; eLisA, enzyme-linked immunosorbent assay; iDDM, 
insulin-dependent diabetic patients.Vascular Health and Risk Management 2009:5 854
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levels, CRP, the lipid markers, age, or body mass index 
(BMI). BMI did not correlate with cholesterol, triglycerides, 
or LDL either. On the other hand, and as expected, BMI 
inversely correlated with HDL-C (-0.264; P  0.001); the 
high CRP levels inversely correlated with high HDL levels 
(-0.242; P  0.001); and cholesterol levels correlated well 
with triglycerides (0.463; P  0.001) and LDL-C (0.847; 
P  0.001).
Fractalkine in coronary artery bypass 
graft surgery and multivessel disease
Among the CHD patients the subgroup of patients who had 
currently received coronary artery bypass graft (CABG) 
surgery were analyzed because these patients express 
the highest pro-inflammatory state prior to rehabilitation. 
However, in the 14 patients of the CHD group who had 
received a CABG within two weeks before attending the 
“Curschmann Klinik für Rehabilitation” (533 ± 288 pg/mL), 
the fractalkine serum levels were not significantly different 
from those in the CHD patients not receiving a bypass (459 
± 203 pg/mL; P = 0.349). In addition, a CHD subgroup of 
patients suffering from multivessel disease with either two 
(496 ± 237 pg/mL) or three (429 ± 215 pg/mL) stenosed 
coronary arteries did not express significantly increased 
fractalkine levels after rehabilitation, as compared to patients 
with only one (507 ± 231 pg/mL) occluded coronary artery 
(P = 0.575).
Discussion
Innate inflammatory pathways are important in atherogenesis. 
Chemokines and adhesion molecules contribute to this 
process. Disease-associated, enhanced levels of adhesion 
molecules, cytokines, or chemokines may be reduced after 
optimal medical treatment during rehabilitation. Thus, 
we compared the serum levels of fractalkine in patients 
with CHD or IDDM following rehabilitation with those 
in healthy control subjects. Furthermore, we investigated 
the relation between fractalkine and classical risk factors 
for atherosclerosis in patients with CHD and IDDM in a 
state of postprandial hyperlipemia. The data show that the 
fractalkine levels of the patients after rehabilitation were at 
the control level or lower. Postprandial hyperlipemia reduced 
the fractalkine levels in control subjects and in vessel wall 
cells in vitro, whereas postprandial hyperlipemia did not 
result in significantly different fractalkine levels in diabetic 
and CHF patients according to ANOVA. These data indicate 
that the fractalkine levels were similar to control values and 
that acute hyperlipemia did not alter fractalkine levels in 
patients, whereas it did so in controls.
Previous studies reported that soluble fractalkine was 
increased in CHD patients as compared to controls, and that 
membrane-bound fractalkine was increased in human carotid 
arteries and in animal models.37,38 In another study serum 
fractalkine levels were determined:22 These data showed 
that patients with unstable angina (1,199 ± 112 pg/mL) had 
enhanced fractalkine levels as compared with control levels 
(423 ± 25 pg/mL) and that six-month atorvastatin therapy, but 
not simvastatin therapy, greatly reduced the fractalkine levels in 
the investigated patients (587 ± 89 pg/mL). These results are in 
line with the data shown in the present manuscript, which are 
in the range of those for the controls or statin-treated patients. 
Fractalkine has been demonstrated to be involved in diabetic 
nephropathy in murine models. Upregulated fractalkine and 
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Figure 3 Reduction in fractalkine levels in lipofundin-treated cultures of vessel 
wall cells. Human vascular smooth muscle cells (20,000 SMC/cm2) were cultured in 
24-well plates.   After 24 hours the medium was changed and fractalkine production 
induced by costimulation with interferon-γ and tumor necrosis factor-α (200 U/ml, 
20 ng/ml, respectively). Parallel cultures were incubated in the presence of various 
concentrations of lipofundin.   After 24 hours, the supernatants were harvested and 
measured by fractalkine eLisA.   Two experiments provided similar results.
Abbreviations: eLisA, enzyme-linked immunosorbent assay; sMc, smooth muscle cells.
Table 2 Classical markers of inflammation and lipid metabolisma
Parameter Unit Control IDDM CHD P valueb
cRP mg/L 2 ± 3 10 ± 16 6 ± 7 0.001
HDL-c mg/dL 45 ± 12 39 ± 22 35 ± 7 0.009
LDL-c mg/dL 127 ± 35 79 ± 38 68 ± 21 0.000
Tc mg/dL 205 ± 35 151 ± 50 124 ± 27 0.000
Triglycerides mg/dL 160 ± 113 145 ± 13 101 ± 45 0.013
Notes: aPatients with insulin-dependent diabetes (iDDM; n = 47) or coronary heart 
disease (cHD; n = 46) were compared to healthy controls (n = 50) at timepoint 0. 
Values are presented as mean ± standard deviation;  bThe p-value for comparison 
between all three groups was calculated by AnOVA.
Abbreviations: cRP,   c-reactive protein;  HDL-c, high-density lipoprotein cholesterol; 
LDL-c, low-density lipoprotein cholesterol;    Tc, total cholesterol.Vascular Health and Risk Management 2009:5 855
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CX3CR1 levels were present in the early stage of diabetic 
kidney disease in rats.28 The aforementioned data suggest 
that fractalkine and CX3CR1 have an important role in the 
progression of diabetic nephropathy, functioning as an arrest 
chemokine in monocyte/macrophage adhesion before migra-
tion into the kidney. Blockade of the renin–angiotensin–aldo-
sterone system and treatment with statins currently represent 
the only clinical strategies for treating the inflammatory process 
in diabetic nephropathy. Newer strategies include chemokine 
receptor antagonists and even immunosuppressive therapy, but 
these are still in the experimental stage. In contrast to the CHD 
patients, no data exist about the fractalkine levels in untreated 
diabetic patients. We are currently addressing this question. 
However, the cited data indicate that fractalkine levels are 
enhanced in CHD patients. The low fractalkine levels in the 
same patient group in the present study suggest an analogous 
reducing effect caused by 1) the rehabilitation process, and/or 
2) alleviating the acute status of the disease.
Serum fractalkine levels in CHD and IDDM patients 
following rehabilitation did not differ from those in healthy 
control subjects. This may partly be explained by the optimal 
medical and lifestyle treatment that patients benefit from 
during rehabilitation. Thus, blood glucose, heart rate, and 
blood pressure are continuously monitored and promptly 
corrected. Furthermore, patients profit from physical activity 
and controlled food intake, ie, lifestyle improvement.39,40
On the other hand, patients with CHD and IDDM in 
rehabilitation are no longer in an acute phase of the disease. 
The baseline characteristics of our study population indicate 
that medical treatment in the two patient groups was more 
prevalent than in control subjects. The majority (96%) of the 
CHD and IDDM patients were on statin therapy compared 
to only 4% in controls. In addition to their lipid-lowering 
activity, statins may also have anti-inflammatory effects. 
During the constrictive remodeling status, statins have the 
ability to stabilize the atherosclerotic plaque.41 In addition, 
their anti-inflammatory effect was measured by their ability 
to lower CRP levels.42,43 The lipid and CRP data in the latter 
publications are in line with those for the control population 
presented here. The lipid data in the present study patients 
also indicate that the treatment had a similarly beneficial 
effect. However, the CRP levels did not reach the control 
values, which might be explained by the type and dose of 
statins used in the current study. This may have influenced 
the expression of the inflammatory parameters.22,41 Other 
therapeutic agents in atherosclerotic diseases include ACE 
inhibitors and ARBs. Both agents can reduce the expression 
of angiotensin I and II receptors on endothelial cells and 
monocytes. Thereby, they may reduce various inflammatory 
processes.42,43 ACE inhibitors and ARB therapy was used in 
72% of the CHD and IDDM patients, compared to only 10% 
among the healthy controls. We hypothesize that the low 
fractalkine levels in the two patient groups may be caused by 
the combined ACE inhibitor, ARB, and statin treatment.
An approximate measure of treatment efficacy is shown 
by the differing responses to postprandial hyperlipemia 
found in the present experiments. Postprandial hyperlipemia 
significantly reduced fractalkine levels in the controls, whereas 
it had no effect in the patients. We assume that this lack of 
response was caused by the anti-inflammatory capacity of the 
drugs being used. On the other hand, the lower (systemic) 
fractalkine levels may reflect reduced shedding, which in 
turn may indicate enhanced vascular inflammation. However, 
this suggestion remains somewhat speculative since no 
corresponding data have been published. However, we found 
that lipid treatment (lipofundin) reduced fractalkine release in 
vascular smooth muscle cells in a dose-dependent fashion in 
in vitro experiments. The reduction in the fractalkine levels 
in the controls also indicates that the selected measurement 
time-points were adequate. Other reports used similar time-
points for postprandial measurements.30,32 On the other hand, 
we found that cytokines could already be detected in bypass 
patients after three hours.44 The enhanced fractalkine level at 
the four-hour time-point may reflect activation of the inflam-
matory genes by insulin.45,46 However, insulin is also known 
to have anti-inflammatory effects.
Similarly to other studies we were not able to show 
any significant correlation between fractalkine levels and 
other classical risk factors for atherosclerosis, such as lipid 
metabolism (HDL-C, LDL-C, TC, and TG), age, BMI, or 
diabetes.22,23 In our study, fractalkine serum levels were not 
significantly elevated in patients who received CABG sur-
gery within two weeks before attending rehabilitation. This 
indicates that the acute inflammatory phase in these patients 
has already subsided. Furthermore, fractalkine levels in 
patients with two or three occluded coronary arteries were 
not higher than those in patients with only one stenosed 
coronary artery. These data suggest that the differences 
in the inflammatory situations between controls and CHD 
patients,22 or as suspected here, between controls and diabetic 
patients are leveled by rehabilitation. Serum fractalkine 
levels are increased in patients with CHD during the acute 
inflammatory state of the disease, such as acute myocardial 
infarction or acute heart failure.22,47 After the acute phase of 
a cardiovascular inflammatory disease optimized medical 
treatment, such as that given during rehabilitation, may Vascular Health and Risk Management 2009:5 856
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decrease the inflammatory status, as shown by the similar 
serum fractalkine levels in patients and healthy controls in 
this study.
Conclusion
Our results demonstrate the relevance of optimized medical 
treatment, such as that given during rehabilitation, for patients 
with CHD and IDDM. The present data show that in CHD 
and diabetic patients, in whom an activated inflammatory 
state is expected, inflammation as determined by serum levels 
of fractalkine was at the control level. Even in an elevated 
inflammatory state caused by postprandial hyperlipemia, no 
significant increase in fractalkine serum levels was found in 
the two patient groups compared to control subjects. The 
results may be explained by the quiescent disease state, 
optimized anti-inflammatory treatment with statins, ACE 
inhibitors and ARBs, and the controlled environment of the 
CHD and IDDM rehabilitation patients.
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